Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
57
24
36
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
3.5%
2 terminated/withdrawn out of 57 trials
75.0%
-11.5% vs industry average
21%
12 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (57)
A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
Role: lead
Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC
Role: lead
SKB315 in Combination Therapy in Patients With Advanced or Metastatic GC/ GEJ Adenocarcinoma
Role: lead
SKB103 for Injection in Advanced Solid Tumors
Role: lead
SKB118 Injection in Advanced Solid Tumors
Role: lead
SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.
Role: lead
A Study of KL130008 in Adults With Severe Alopecia Areata
Role: lead
A Phase II Study of SKB571 in Patients With Lung Cancer
Role: lead
Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial
Role: lead
SKB410 for Injection in Solid Tumors
Role: lead
Safety and Pharmacokinetics of Recombinant Anti-EGFr Antibody in Patients With Metastatic Colorectal Cancer
Role: lead
A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors
Role: lead
A Study of SKB571 in Participants With Gastrointestinal Tumors
Role: lead
A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities
Role: lead
Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Role: lead
A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
Role: lead
A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors
Role: lead
A Study of Intratumoral KL340399 in Patients With Advanced Solid Tumors
Role: lead
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Role: lead
A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy
Role: lead